Biohaven Pharmaceutical’s shares were down 2.4% in early trading on Tuesday, dropping to $14.03, after the company announced a global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel platform.
Under the terms of the deal, Biohaven granted SK Biopharmaceuticals exclusive worldwide rights to its Kv7 platform, which includes the lead epilepsy candidate opakalim (BHV-7000). The transaction includes an upfront cash payment of $400 million, with total consideration potentially reaching $795 million upon achievement of certain milestones.
The agreement removes opakalim’s Phase 2/3 RISE3 trial from Biohaven’s internal pipeline. The trial’s topline readout had been one of the most anticipated binary events on the company’s 2026 calendar, with its potential outcome previously viewed as a major catalyst for Biohaven’s stock performance.
Biohaven’s remaining pipeline includes immunology programs BHV-1300 (targeting Graves’ disease) and BHV-1400 (for IgA nephropathy), alongside several oncology candidates. The company also faces a separate legal development, having secured a $4 million trade secret judgment in its favor against RA Capital and Avilar Therapeutics on August 24.
Analyst sentiment toward Biohaven has been cautious, with Bank of America downgrading the stock to Underperform in late June 2026. The downgrade cited concerns over the risk-reward profile of Kv7 epilepsy data and the company’s cash runway.
U.S. equity benchmarks, including the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite, were trading essentially flat during the session.
